Dr. Fuster is Associate Professor, Head of the Hematovascular Pathophysiology Laboratory, and Coordinator of the Atherosclerosis Research Program at CNIC.
The Hematovascular Pathophysiology Laboratory is focused on evaluating new mechanisms that link clonal hematopoiesis to cardiovascular and metabolic disorders, with an especial interest in context of aging. Their research combines human studies, both cross-sectional and longitudinal, to elucidate the associations between CH and cardiovascular disease, and experimental studies to provide causal evidence and mechanisms of action for the observations made in the human cohorts.
Dr. Pascual is the leader of the Experimental and Clinical Cardiology group at the IMIB (Instituto Murciano de Investigación Biosanitaria, part of FFIS). He is also a Professor of Cardiology at the University of Murcia, and Head of the Cardiology Department at the University Clinical Hospital Virgen de la Arrixaca.
His research activity focuses in the field of cardiovascular diseases, heart failure and biomarkers, including the role of clonal hematopoiesis in heart failure.
Dr. Bayés-Genís is the Head of ICREC (Heart Failure and Cardiac Regeneration Laboratory) and Director of iCor (Heart Research Institute at IGTP), Cardiology Chief at Trias i Pujol Hospital and Associate Professor at the University Autónoma de Barcelona.
ICREC group focuses on both basic and clinical research approaches to heart failure and cardiac regeneration. They work on the identification of prognostic factors and biomarkers of heart failure progression. Additionally, they have a translational focus, working also with stem cells and tissue engineering to develop biocompatible patches and polymers to regenerate heart tissue.
Dr. López-Bigas is a Research Professor at the IRBB, Associate Professor at the University Pompeu Fabra, and leader of the Biomedical Genomics lab at IRBB.
The Biomedical Genomics (BBGLab) research group is focused on the study of cancer and somatic tissues in general from a genomics perspective. They have made major contributions in the identification of cancer genes and cancer driver mutations across tumor types; in understanding the mutational processes that lead to the accumulation of mutations in tumors and in the analysis of the effect of chemotherapy in the DNA of treated patients. They have recently started contributed to the study of genes and mutations driving Clonal Hematopoiesis by repurposing tools, concepts originally developed within cancer genomics.
Dr Manel Esteller Badosa is the director of the Josep Carreras Leukaemia Research Institute and leader of the Cancer Epidenetics group. He is also a researcher at ICREA (Institución Catalana de Investigación y Estudios Avanzados), and Full Professor of Genetics at the University of Barcelona.
His research focuses on understanding of the molecular and cellular defects involved in human disease, particularly cancer. He has pioneered the study of epigenetic aberrations in oncology among many different tumor types, findings that have changed our view of the disease and led to the discovery of novel biomarkers and drugs, some now in clinical use. Most recently, he has also collaborated with specialists in cardiovascular diseases to study the link between epigenetic alterations and their impact on myocardial infarction and the atherothrombosis process. With the ambition to bring light to the epigenetic disease mechanisms.
Myoclonal is a CNIC Website